Home > News > BioSante Pharmaceuticals Reports Product Development Highlights
May 16th, 2005
BioSante Pharmaceuticals Reports Product Development Highlights
Abstract:
BioSante Pharmaceuticals (AMEX:BPA) today reported on certain product development highlights and announced financial results for the first quarter ended March 31, 2005.
"The completion of our pivotal Phase III clinical trial of Bio-E-Gel(TM) and two key announcements highlighting the use of our CaP nanotechnology represent important progress for BioSante," said Stephen M. Simes, BioSante's president and chief executive officer.
Source:
genengnews.com
Bookmark:
Nanomedicine
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
European Technology Platform for Nanomedicine and Nanomed2020 European Consortium Launch the Nanomedicine Award June 17th, 2013
Announcements
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Financial Reports
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Harris & Harris Group Reports Financial Statements as of March 31, 2013 May 10th, 2013
Arrowhead Reports Fiscal 2013 Second Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time May 9th, 2013
Arrowhead to Report Fiscal 2013 Second Quarter Financial Results - Conference Call Scheduled for Thursday, May 9, 2013 May 2nd, 2013